← Back to headlines
J.P. Morgan downgrades Dyne following Novartis setback
Shares of Dyne Pharmaceuticals extended their decline after J.P. Morgan issued a downgrade, citing setbacks associated with partner company Novartis.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
